Edition:
United States

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

22.04USD
13 Dec 2017
Change (% chg)

$1.00 (+4.75%)
Prev Close
$21.04
Open
$21.07
Day's High
$22.18
Day's Low
$21.07
Volume
150,475
Avg. Vol
106,154
52-wk High
$26.43
52-wk Low
$15.57

Latest Key Developments (Source: Significant Developments)

Retrophin reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:21pm EST 

Nov 7 (Reuters) - Retrophin Inc :Retrophin reports third quarter 2017 financial results.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.46.Q3 adjusted non-GAAP earnings per share $0.15.  Full Article

Retrophin considering acquisition of Raptor Pharmaceutical- Bloomberg
Wednesday, 17 Aug 2016 08:00pm EDT 

:Retrophin Inc considering acquisition of Raptor Pharmaceutical Corp - Bloomberg, citing sources.  Full Article

Retrophin posts Q2 adj EPS $0.07, net product sales $33.2 mln
Thursday, 4 Aug 2016 04:01pm EDT 

Retrophin Inc : Q2 adjusted non-gaap earnings per share $0.07 . Q2 revenue rose 38 percent . Retrophin reports second quarter 2016 financial results . Q2 loss per share $0.37 . Retrophin inc says net product sales for q2 of 2016 were $33.3 million, compared to net product sales of $24.1 million for same period in 2015 .Says remains on track to initiate its efficacy trial evaluating RE 024 in pkan during second half of 2016.  Full Article

Martin Shkreli faces June 2017 trial date in fraud case
Thursday, 14 Jul 2016 02:23pm EDT 

: Trial date set by federal judge at hearing in Brooklyn, New York.  Full Article

Retrophin buys liquid formulation of Ursodeoxycholic acid
Monday, 20 Jun 2016 04:30pm EDT 

Retrophin Inc : Made an upfront payment of $0.5 million and will make future payments of up to $23.5 million based on cumulative sales milestones . Intends to file a new drug application with U.S. FDA for liquid formulation of ursodeoxycholic acid in 2017 . Asklepion will be eligible to receive incremental milestone payments of up to $35.0 million upon successful development and commercialization . Will assume all future program costs and pay asklepion tiered royalties on future product sales .Retrophin acquires liquid formulation of ursodeoxycholic acid.  Full Article

Retrophin Inc reiterates FY 2016 revenue guidance
Tuesday, 3 May 2016 04:01pm EDT 

Retrophin Inc:FY 2016 revenue guidance of $130.0 to $140.0 million reiterated.  Full Article

Retrophin Inc board approves $40 mln share repurchase
Tuesday, 3 May 2016 04:01pm EDT 

Retrophin Inc:board of directors has approved repurchase of up to an aggregate $40.0 million of its common stock.  Full Article

Retrophin Inc names Gary A. Lyons Chairman of the Board of Directors
Monday, 4 Apr 2016 04:30pm EDT 

Retrophin Inc:Gary A. Lyons will become company's next independent Chairman of Board of Directors.Says Gary A. Lyons will succeed current Chairman Jeffrey A. Meckler.  Full Article

Retrophin Inc receives European orphan drug designation for RE-024 for treatment of pantothenate kinase-associated neurodegeneration
Wednesday, 24 Feb 2016 08:30am EST 

Retrophin Inc:Receives European orphan drug designation for RE-024 for treatment of pantothenate kinase-associated neurodegeneration.  Full Article

Retrophin Inc to pay $3 million in U.S. lawsuit over Shkreli's tenure - Reuters
Wednesday, 3 Feb 2016 08:26am EST 

Retrophin Inc:Retrophin Inc has agreed to pay $3 million to resolve a lawsuit by investors accusing the pharmaceutical company of failing to disclose various transactions that benefited former Chief Executive Officer Martin Shkreli, who has since been indicted for securities fraud - RTRS.The proposed class action settlement, which also resolves claims against Shkreli, was filed in federal court in Manhattan on Friday and granted preliminary approval by U.S. District Judge Kevin Castel on Tuesday.The $3 million settlement equals 7 percent to 10 percent of the $26 million to $41 million in likely recoverable damages, according to lead plaintiff Grachya Kazanchyan's lawyers at Pomerantz LLP, who in turn plan to seek $1 million in legal fees.The lawsuit centers on many of the same allegations at the heart of the criminal case in federal court in Brooklyn against Shkreli, who founded Retrophin and was fired in 2014, the same year the lawsuit was filed.  Full Article

BRIEF-Retrophin reports third quarter 2017 financial results

* Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S